Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | POLRMT | O00411 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120060 | 0.98 | TMPRSS2 (0.41) | TMPRSS2POLRMTP2RY2P2RY4P2RX1 | |
| SCHEMBL17719216 | 0.93 | TMPRSS2 (0.44) | TMPRSS2 | |
| SCHEMBL4765700 | 0.91 | POLRMT (0.38) | TMPRSS2POLRMTP2RY2P2RY4P2RX1 | |
| SCHEMBL10120062 | 0.90 | POLRMT (0.40) | POLRMTP2RY2P2RY4P2RY6P2RX1 | |
| SCHEMBL17719210 | 0.88 | TMPRSS2 (0.40) | TMPRSS2P2RY2P2RY6 | |
| SCHEMBL17719238 | 0.88 | POLRMT (0.48) | TMPRSS2POLRMTP2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492745 | 0.86 | POLRMT (0.51) | TMPRSS2POLRMTP2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL10120881 | 0.86 | POLRMT (0.51) | TMPRSS2POLRMTP2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL23278555 | 0.86 | POLRMT (0.51) | TMPRSS2POLRMTP2RX1P2RX3P2RX2 | |
| Rdv-Tp SCHEMBL24492746 | 0.86 | POLRMT (0.51) | TMPRSS2POLRMTP2RX1P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885P2RY2 565/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885P2RY2 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.